RCUS Arcus Biosciences Inc: Enterprise Value-to-Revenue Multiple

Public company logo of arcusbio.com (RCUS)

Arcus Biosciences, Inc. (RCUS) possesses high scientific authority in developing targeted immuno-oncology agents. A diversification strategy through partnerships with industry behemoths mitigates risks, as the company's price-to-sales trend on GURU.Markets illustrates through valuation dynamics. The value 17581.70 serves as the current metric level, while the asset's market price is based exclusively on the success of clinical trials.

Company Value to Revenue: Arcus Biosciences Inc (RCUS) for 11/23/2025 - 11/20/2026

arcusbio.com - analytical breakdowns and key metrics (RCUS)

- share price and consensus valuation forecast:
Initial company analysis:Arcus Biosciences, Inc. RCUS
Product sample of Arcus Biosciences, Inc.

This ratio determines the market value of the business, including net debt, relative to sales volume. By analyzing the enterprise value-to-revenue level, an investor identifies the degree of asset overheating relative to actual cash flows. The metric eliminates the impact of leverage, exposing the true fundamental valuation. For Arcus Biosciences, Inc. (RCUS), this allows for an assessment of how much the market has priced in the success of immuno-oncology developments and the effectiveness of strategic partnerships. A sharp increase in the indicator may signal inflated expectations for future clinical successes.

Competitor analysis for Arcus Biosciences, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue ZYME|TNGX - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP